Promise of UCB's gMG candidates picked up on by journal

Data from UCB’s Phase III studies of rozanolixizumab and zilucoplan in generalized myasthenia gravis (gMG) have been published in The Lancet Neurology.

Both drugs are investigational therapies currently under regulatory review in the USA, Europe and Japan.

"These results bring us one step forward towards offering tailored options to meet individual patient needs"Findings from the MycarinG study were published, showing the clinically-meaningful and statistically-significant effects of rozanolixizumab across key endpoints in adults with acetylcholine receptor autoantibody positive (AChR-Ab+) or muscle-specific tyrosine kinase (MuSK-Ab+) autoantibody positive gMG, in the largest study in patients with gMG to date.